PVG Asset Management Corp acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, HoldingsChannel reports. The firm acquired 14,367 shares of the biopharmaceutical company’s stock, valued at approximately $970,000.
A number of other large investors also recently modified their holdings of GILD. Renaissance Technologies LLC lifted its stake in Gilead Sciences by 56.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock valued at $860,731,000 after acquiring an additional 4,620,000 shares in the last quarter. Invesco Ltd. raised its stake in shares of Gilead Sciences by 17.5% during the 2nd quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock worth $1,552,213,000 after purchasing an additional 3,418,193 shares during the period. Marshall Wace North America L.P. raised its stake in shares of Gilead Sciences by 298.3% during the 2nd quarter. Marshall Wace North America L.P. now owns 3,418,196 shares of the biopharmaceutical company’s stock worth $230,934,000 after purchasing an additional 2,559,972 shares during the period. Miller Howard Investments Inc. NY bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $93,386,000. Finally, First Trust Advisors LP raised its stake in shares of Gilead Sciences by 77.8% during the 2nd quarter. First Trust Advisors LP now owns 2,825,707 shares of the biopharmaceutical company’s stock worth $190,905,000 after purchasing an additional 1,236,379 shares during the period. Institutional investors and hedge funds own 79.57% of the company’s stock.
In related news, Director Olsen Per Wold sold 4,908 shares of Gilead Sciences stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total value of $313,670.28. Following the completion of the sale, the director now owns 102,762 shares of the company’s stock, valued at approximately $6,567,519.42. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 608 shares of Gilead Sciences stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. In the last three months, insiders sold 12,716 shares of company stock valued at $821,299. 0.20% of the stock is currently owned by insiders.
GILD traded up $0.79 during trading hours on Friday, hitting $66.75. The stock had a trading volume of 2,987,742 shares, compared to its average volume of 5,563,156. The company’s fifty day simple moving average is $64.41 and its 200 day simple moving average is $65.46. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The stock has a market cap of $83.80 billion, a PE ratio of 10.85, a price-to-earnings-growth ratio of 3.14 and a beta of 1.10. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same quarter last year, the firm posted $1.91 EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 6.66 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.78%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: What are economic reports?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.